Remus Pharmaceuticals (NSE:REMUS) Common Stock: ₹118 Mil (As of Mar. 2026)


NSE:REMUS Remus Pharmaceuticals Ltd NSE:REMUS
61 GF Score
Price ₹739.95
GF Value ₹2,071.36
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Remus Pharmaceuticals Common Stock?

Remus Pharmaceuticals NSE:REMUS -1.04% 61 Common Stock is ₹118 Mil as of Mar. 2026. GuruFocus rates NSE:REMUS with a GF Score™ of 61/100 and a GF Value™ of ₹2,071.36 (Significantly Undervalued). The stock has 2 warning signs investors should review.

Remus Pharmaceuticals's quarterly common stock increased from Mar. 2025 (₹59 Mil) to Sep. 2025 (₹118 Mil) but then stayed the same from Sep. 2025 (₹118 Mil) to Mar. 2026 (₹118 Mil).

Remus Pharmaceuticals's annual common stock increased from Mar. 2024 (₹15 Mil) to Mar. 2025 (₹59 Mil) and increased from Mar. 2025 (₹59 Mil) to Mar. 2026 (₹118 Mil).

Remus Pharmaceuticals Common Stock Historical Data

* Premium members only.

The historical data trend for Remus Pharmaceuticals's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Remus Pharmaceuticals Common Stock Chart

Remus Pharmaceuticals Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Common Stock
Get a 7-Day Free Trial 10.00 10.90 14.70 58.90 117.80

Remus Pharmaceuticals Semi-Annual Data
Mar20 Mar21 Mar22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.70 58.92 58.90 117.80 117.80
NSE:REMUS
61GF Score
Remus Pharmaceuticals Ltd NSE:REMUS
Common Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Remus Pharmaceuticals Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of ₹118 Mil mean?
Remus Pharmaceuticals (NSE:REMUS) has a Common Stock of ₹118 Mil as of Mar. 2026. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Remus Pharmaceuticals and its competitors.
Is Remus Pharmaceuticals' Common Stock too high?
Remus Pharmaceuticals' current Common Stock is ₹118 Mil. Overall, Remus Pharmaceuticals has a GF Score™ of 61/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Remus Pharmaceuticals' Common Stock compare to MCK and CAH?
Remus Pharmaceuticals' Common Stock of ₹118 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Medical Distribution company?
A good Common Stock depends on the Medical Distribution industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Remus Pharmaceuticals and its competitors. Remus Pharmaceuticals's current Common Stock is ₹118 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Remus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Remus Pharmaceuticals (NSE:REMUS) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹2,071.36, compared to a current price of ₹739.95 — trading 64.3% below its estimated fair value. The current Common Stock is ₹118 Mil. Remus Pharmaceuticals' overall GF Score™ is 61/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For Remus Pharmaceuticals (NSE:REMUS), the current Common Stock is ₹118 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Remus Pharmaceuticals (NSE:REMUS) Overvalued in 2026?

Based on GuruFocus' analysis, Remus Pharmaceuticals stock appears to be undervalued. The current stock price of ₹739.95 is trading 64.3% below its estimated GF Value™ of ₹2,071.36. GuruFocus considers Remus Pharmaceuticals to be Significantly Undervalued.

Key valuation signals for NSE:REMUS:

  • Common Stock: ₹118 Mil
  • GF Value™: ₹2,071.36 vs. price of ₹739.95 (64.3% below fair value)
  • GF Score™: 61/100 with 2 warning signs

No single metric tells the full story. See the NSE:REMUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Remus Pharmaceuticals Business Description

Address Ambli bopal Road, 1101 to 1103, South Tower, One 42, Behind Ashok Vatika, Near Jayantilal Park BRTS, Ahmedabad, GJ, IND, 380054
Remus Pharmaceuticals Ltd is engaged in the marketing & distribution of finished formulations of pharmaceutical drugs. The company also deals in API (Active Pharmaceutical Ingredient). It also provides technical consultancy services to various distributors for the preparation of reports on the dossiers of the products to be registered by them in various countries. Remus Pharmaceuticals market niche medicinal combinations. It exports generic drugs by conducting intensive market research in the pharmaceutical industry to expand its product portfolio.
61GF Score

Get the complete analysis for NSE:REMUS

Common Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹739.95
Price
₹2,071.36
GF Value